Late clinical presentation of congenital adrenal hyperplasia in older children: Findings from national paediatric surveillance

Archives of Disease in Childhood

Volumn 99, Issue 1, 2014, Pages 30-34

  Knowles, Rachel L ^a   Khalid, Javaria M ^a   Oerton, Juliet M ^a   Hindmarsh, Peter C ^b   Kelnar, Christopher J ^c   Dezateux, Carol ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE AGE; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; FEMALE; GESTAGEN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN SCREENING; OBESITY; PRECOCIOUS PUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALT WASTING; SCHOOL CHILD; STEROID 21 MONOOXYGENASE DEFICIENCY;

CONGENITAL ABNORM; ENDOCRINOLOGY; EPIDEMIOLOGY;

17-ALPHA-HYDROXYPROGESTERONE; ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; CHILD; CHILD, PRESCHOOL; DELAYED DIAGNOSIS; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; NEONATAL SCREENING; POPULATION SURVEILLANCE; STEROID 21-HYDROXYLASE;

EID: 84890559905     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-303070     Document Type: Article

References (21)

1. New MI. An update of congenital adrenal hyperplasia. Ann NY Acad Sci 2004;1038:14-43.
2. Khalid JM, Oerton JM, Dezateux C, et al. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Arch Dis Child 2012;97:101-06.
3. Thilen A, Larsson A. Congenital adrenal hyperplasia in Sweden 1969-1986. Prevalence, symptoms and age at diagnosis. Acta Paediatr Scand 1990;79:168-75.
4. Eugster EA, DiMeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001;138:26-32.
5. Cornean RE, Hindmarsh PC, Brook CGD. Obesity in 21-hydroxylase deficient patients. Arch Dis Child 1998;78:261-63.
6. Völkl TMK, Simm D, Beier C, et al. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatr 2006;117:e98-105.
7. Stout SA, Litvak M, Robbins NM, et al. Congenital adrenal hyperplasia: classification of studies employing psychological endpoints. Int J Pediatr Endocrinol 2010;2010:191520..
8. Arlt W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95:5110-21.
9. Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr 2011;76:73-85.
10. Gleeson HK, Wiley V, Wilcken B, et al. Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J Paediatr Child Health 2008;44:554-59.
11. Van der Kamp HJ, Noordam K, Elvers B, et al. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatr 2001;108:1320-4.
12. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998;17:407-29.
13. The NHS Health and Social Care Information Centre, Lifestyle Statistics. National Child Measurement Programme: England, 2007/08 school year. The NHS Health and Social Care Information Centre, 2008. http://www.hscic.gov.uk/ catalogue/PUB02314 (accessed 5 May 2013).
14. Office for National Statistics. Population estimates by ethnic group for local authority districts and higher administrative areas in England and Wales for 2009: EE2. Office for National Statistics, 8th edn. London, 2011.
15. Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods and limitations. Epidemiol Rev 1995;17:243-64.
16. Sarafoglou K, Lorentz C, Otten N, et al. Molecular testing in congenital adrenal hyperplasia due to 21alpha-hydroxylase deficiency in the era of newborn screening. Clin Genet 2012;82:64-70.
17. Speiser PW, Dupont B, Rubinstein P. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985;37:650-67.
18. Nordenström A, Thilén A, Hagenfeldt L, et al. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999;84:1505-09.
19. Virdi NK, Rayner PH, Rudd BT, et al. Should we screen for congenital adrenal hyperplasia? A review of 117 cases. Arch Dis Child 1987;62:659-62.
20. Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm Res 2007;67:284-91.
21. Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. Pediatr 2006;117(5 Pt 2):S287-95.